ResMed Inc. $RMD Shares Sold by Savant Capital LLC

Savant Capital LLC lessened its position in ResMed Inc. (NYSE:RMD) by 56.3% in the 4th quarter, Holdings Channel reports. The fund owned 4,213 shares of the medical equipment provider’s stock after selling 5,431 shares during the period. Savant Capital LLC’s holdings in ResMed were worth $1,015,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in RMD. International Assets Investment Management LLC purchased a new stake in shares of ResMed in the 4th quarter valued at approximately $25,000. ORG Partners LLC lifted its position in shares of ResMed by 181.6% in the 4th quarter. ORG Partners LLC now owns 107 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 69 shares in the last quarter. Imprint Wealth LLC purchased a new stake in shares of ResMed in the 3rd quarter valued at approximately $26,000. WFA of San Diego LLC purchased a new stake in shares of ResMed in the 2nd quarter valued at approximately $26,000. Finally, Sunbelt Securities Inc. purchased a new stake in shares of ResMed in the 3rd quarter valued at approximately $31,000. Hedge funds and other institutional investors own 54.98% of the company’s stock.

Insider Buying and Selling at ResMed

In other news, CEO Michael J. Farrell sold 4,991 shares of the stock in a transaction on Monday, March 9th. The shares were sold at an average price of $251.03, for a total transaction of $1,252,890.73. Following the transaction, the chief executive officer owned 466,223 shares in the company, valued at $117,035,959.69. This represents a 1.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $225.00, for a total transaction of $450,000.00. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 16,973 shares of company stock worth $3,865,591. 0.65% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on RMD shares. Weiss Ratings downgraded shares of ResMed from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 22nd. Robert W. Baird set a $225.00 price target on shares of ResMed in a research report on Friday, May 1st. Evercore set a $255.00 price target on shares of ResMed and gave the company an “outperform” rating in a research report on Monday, April 13th. Wells Fargo & Company dropped their price objective on shares of ResMed from $270.00 to $227.00 and set an “equal weight” rating on the stock in a research note on Friday, May 1st. Finally, Royal Bank Of Canada upped their price objective on shares of ResMed from $314.00 to $321.00 and gave the company an “outperform” rating in a research note on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, ResMed has an average rating of “Moderate Buy” and a consensus price target of $286.18.

ResMed Stock Performance

Shares of RMD opened at $183.01 on Wednesday. The company’s fifty day moving average is $216.11 and its 200-day moving average is $238.80. ResMed Inc. has a 12 month low of $180.26 and a 12 month high of $293.81. The firm has a market cap of $26.55 billion, a price-to-earnings ratio of 17.65, a price-to-earnings-growth ratio of 1.19 and a beta of 0.80. The company has a quick ratio of 2.33, a current ratio of 3.01 and a debt-to-equity ratio of 0.06.

ResMed (NYSE:RMD) last announced its quarterly earnings results on Thursday, April 30th. The medical equipment provider reported $2.86 EPS for the quarter, topping the consensus estimate of $2.79 by $0.07. ResMed had a net margin of 27.44% and a return on equity of 25.35%. The company had revenue of $1.43 billion for the quarter, compared to analyst estimates of $1.42 billion. During the same quarter in the prior year, the business posted $2.37 EPS. ResMed’s quarterly revenue was up 10.8% on a year-over-year basis. Equities analysts expect that ResMed Inc. will post 11.13 EPS for the current fiscal year.

ResMed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 18th. Stockholders of record on Thursday, May 14th will be paid a dividend of $0.60 per share. The ex-dividend date is Thursday, May 14th. This represents a $2.40 annualized dividend and a dividend yield of 1.3%. ResMed’s dividend payout ratio is 23.14%.

About ResMed

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.